Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda

Bristol Myers Squibb might have popularized the concept of using tumor mutational burden to identify patients most likely to benefit from checkpoint inhibitors, but Merck’s ever dominant Keytruda is claiming the first approval based on the biomarker.